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this task is to find a way to block a 300–400 kDa interac-A Third Mode of Integrin
tion with a 0.5 kDa molecule.Antagonism The key to antagonizing integrin function was the real-
ization that, in addition to their role as adhesion regula-
tors, integrins are key signal transducing molecules that
relay information about the environment into the cell
and that send signs of activation state from the cell
to its neighbors. Both the adhesion and bidirectionalThrough the biochemical dissection of conformational
signaling roles are regulated by changes to the proteins’changes, Shimaoka et al. (this issue of Immunity) have
three dimensional structures. Work over the past de-delineated a novel role for the I-like domain in the
cade using epitope “fingerprints” and conformationallyallosteric regulation of LFA-1 function and signaling.
locked I-domains has allowed the dissection of confor-This work advances our understanding of LFA-1 an-
mational changes to various integrin domains and thetagonism and reveals new avenues for approaching
association of these changes with different activationLFA-1, and potentially other I-domain containing in-
states (Shimaoka et al., 2002). A convincing model hastegrins, as drug targets.
emerged wherein signaling from inside the cell is initi-
ated by the dissociation of the cytoplasmic tails of the
The exact cause of the massive power outage that dark- integrin’s two subunits leading to the propagation of
ened parts of the United States and Canada last month extracellular conformational changes and culminating in
has not yet been pinpointed, but what is clear from the the opening of an extended conformation at the external
cross-border barrage of accusations is that there are ligand binding site. Signals in the other direction are
a number of potential ways to interfere with complex induced by ligand binding in a reverse fashion starting
signaling systems. with the equilibrium-induced stabilization of the ex-
This is also one of the take-home messages delivered tended conformation which transmits structural changes
in the paper by Shimaoka and coworkers (2003, this into the cell, leading to the separation of the cytoplasmic
issue) who have demonstrated that a class of LFA-1 tails and allowing intracellular processes emanating
antagonists, originally thought to bind to the  chain from the integrin to initiate. This system of using do-
MIDAS domain as ligand mimetics (Gadek et al., 2002), mains as free moving gears that can be locked into place
bind to a site on the2 subunit and cause conformational from either end allows for the bidirectional recognition of
changes distinct from those caused by the well-estab- signals.
lished I-domain allosteric antagonists (Giblin and Kelly, But ligands and intracellular signals are not the only
2001). This marks the third mode of integrin antagonism factors that can influence the position of these gears.
and will certainly have an immediate impact on the de- Small molecule inhibitors of several integrins have
sign of novel therapeutic agents. However, beyond been discovered. The first successes came through the
opening up opportunities for inhibiting integrin function, use of ligand-based design stemming from the discov-
the authors have also biochemically dissected the con- ery that the tripeptide arginine-glycine-aspartic acid
formational changes in the LFA-1 protein that occur (R-G-D) could inhibit the binding of iib3 to its ligandupon binding of these molecules. The molecules bind fibrinogen. Two molecules based on this approach are
to a site on the 2 subunit, yet affect both the  and  approved for clinical use, and other integrins are being
subunits. The result is a protein that is activated in one
targeted using analogous ligand mimetic approaches.
direction and antagonized in the other. Taken together
In addition to acting as competitive ligand antagonists,
with the growing body of work on integrin structure and
many of these molecules also induce the presence offunction, the work provides a link between the physical
activation epitopes, indicating an active configurationevent of ligand binding and the downstream physiologi-
of the cytoplasmic tails (Shimaoka et al., 2002).cal consequence of signal agonism and/or antagonism.
LFA-1 (L2) is also a clinically validated targetThe integrins are cell surface adhesion molecules that
(through antibody work) but is, to date, unique in thecontrol many cell-cell interactions (Hynes, 1992). In the
world of integrins in that the most advanced small mole-circulation, they regulate platelet aggregation (e.g.,
cule drug candidates were discovered through optimi-iib3), tumor metastasis and growth (e.g., v3, v5),
zation of high-throughput screening hits and were notand leukocyte migration and activation (e.g., L2, M2,
designed based on ligand mimicry (Giblin and Kelly,D2,41,47). As such, they have become an important
2001). These compounds bind to an allosteric site onclass of molecules for pharmaceutical intervention. Anti-
the I-domain of the  subunit and prevent ligand bindingbody-based approaches have targeted many of these
by stabilizing the ligand binding domain in a low-affinitymolecules, resulting in clinically useful treatments for
state (Shimaoka et al., 2001). The elicitation of activationpsoriasis (L2) (Gottlieb et al., 2002) and thrombosis
epitopes is also inhibited by these molecules, indicating(iib3) (Hamm, 2003). However, antibody treatments re-
that the whole protein remains in an inactive statequire injections, and there has been a strong interest
(Woska et al., 2001).in discovering small, orally bioavailable molecules that
match the potency of these biologics. The challenge of The third mode of integrin antagonism, as explained
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regulate the intensity, duration, and quality of responsesDefining Control: Regulation of
to cytokines. SOCS protein expression is induced byDendritic Cell Activation and cytokines, and once expressed SOCS proteins function
as components of a negative feedback loop to inhibitImmune Homeostasis by SOCS1
the cytokine signaling pathway. A prototypic member
of this family, SOCS1, appears to play a pivotal role in
the regulation of immune homeostasis. SOCS1-deficient
SOCS1 is a key regulator of cytokine signaling and mice die neonatally from the toxic effects of uncontrolled
is important for maintaining balance in the immune interferon- (IFN) signaling, implicating SOCS1 as a
system. In addition to roles in T, NKT, and macrophage critical regulator of this inflammatory cytokine (Alexan-
cell function, a new study indicates that SOCS1 modu- der et al., 1999).
lates dendritic cell activation and may help prevent Given the neonatal mortality and complex inflamma-
autoimmunity. tory pathology of SOCS1/ mice, many groups have
adopted strategies whereby SOCS1 deficiency is gener-
The response to infection and maintenance of immune ated in the context of a healthy adult mouse, in order
homeostasis requires precise coordination of many cell to define the role of SOCS1 in different cell lineages.
types. Communication between cells is key to sustaining Studies of mice lacking both SOCS1 and IFN, which are
a balanced immune system. Some of the important me- healthy and survive to adulthood, have shown SOCS1 to
diators of communication between cells are secreted be crucial for the maintenance of T cell homeostasis
proteins known as cytokines. Once produced, cytokines (Cornish et al., 2003). Specific deletion of SOCS1 from
bind to specific receptors on the surface of target cells T and NKT cells alone, however, is insufficient to induce
and activate many intracellular signaling pathways, the inflammation characteristic of SOCS1/ mice, indi-
among which the best defined is the janus kinase (JAK)/ cating that the absence of SOCS1 in other tissues also
signal transducer and activator of transcription (STAT) contributes to this disease (Chong et al., 2003). A role
pathway. Activated STATs dimerize and accumulate in for SOCS1 in innate immunity has been shown by injec-
the nucleus where they increase the transcription of tion of SOCS1/ IFN/ mice with LPS. SOCS1-defi-
genes required for induction of the appropriate biologi- cient mice were highly sensitive to LPS-induced lethal-
cal response. Responses to these potent molecules are ity, and LPS-induced macrophage activation was
typically transient and in the absence of appropriate similarly perturbed (Kinjyo et al., 2002).
regulation lead to imbalance in the immune system, re- In this issue of Immunity, a paper by Hanada et al.
sulting on one hand in immunodeficiency and on the describes a novel twist on this approach. This group
other in autoimmunity and inflammation. generated SOCS1-deficient mice in which SOCS1 ex-
pression was restored specifically in T and B lympho-The suppressor of cytokine signaling (SOCS) proteins
